Related Experiment Video
Updated: Jul 15, 2026

Bidirectional Retroviral Integration Site PCR Methodology and Quantitative Data Analysis Workflow
Published on: June 14, 2017
Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined
B E Strauss1, E Costanzi-Strauss
1Setor de Vetores Virais, Laboratório de Genética e Cardiologia Molecular, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil. bstrauss@usp.br
Abstract:
A successful gene therapy clinical trial that also encountered serious adverse effects has sparked extensive study and debate about the future directions for retrovirus-mediated interventions. Treatment of X-linked severe combined immunodeficiency with an oncoretrovirus harboring a normal copy of the gammac gene was applied in two clinical trials, essentially curing 13 of 16 infants, restoring a normal immune system without the need for additional immune-related therapies. Approximately 3 years after their gene therapy, tragically, 3 of these children, all from the same trial, developed leukemia as a result of this experimental treatment. The current understanding of the mechanism behind this leukemogenesis involves three critical and cooperating factors, i.e., viral integration, oncogene activation, and the function of the therapeutic gene. In this review, we will explore the causes of this unwanted event and some of the possibilities for reducing the risk of its reoccurrence.
More Related Videos
Related Concept Videos
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Retroviruses
Tumor Immunotherapy

